8:20 am – 8:30 am: Early Insights from Real-World Use of Aflibercept 8 mg Among Eyes with Neovascular Age-Related Macular Degeneration Switching from Other Anti-VEGF Agents. Jia-Horung Hung, MD, PhD

8:30 am – 8:40 am: Severe IOI in Faricimab - Case Report and Review of Literature. Stephen J. Smith, MD

8:40 am – 8:50 am: Update on Tyrosine Kinase Inhibitors for Wet AMD and DME. Diana V. Do, MD

8:50 am – 9:00 am: Ixoberogene Soroparvovec (Ixo-vec) Gene Therapy for nAMD: Long-Term OPTIC Results. Diana V. Do, MD

9:00 am – 9:10 am: Real-World Outcomes of Anti-Complement Therapies for Geographic Atrophy. Rosa Y. Kim, MD

9:10 am – 9:20 am: Automated Quantification of Decreased Autofluorescence Lesions in Geographic Atrophy Secondary to Age-Related Macular Degeneration. Mohamed Ibrahim Ahmed, MBBCh, MD, MSc

9:20 am – 9:30 am: Phase 2 Results of Oral Plasma Kallikrein Inhibitor for Patients with Diabetic Macular Edema. Robert B. Bhisitkul, MD, PhD

9:30 am – 9:40 am: Update on Future Therapies for Macular Ischemia. Quan Dong Nguyen, MD, MSc

9:40 am – 9:50 am: Panel discussion